Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

eMI Aesthetics vs NuuVim

eMI Aesthetics
Graded #104

Higher grade

vs+2.0999999999999943
NuuVim
Graded #153

Lower grade

The verdict

eMI Aesthetics takes it — 70.3/100 to 68.2/100.

eMI Aesthetics grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. eMI Aesthetics is a US direct-to-consumer telehealth brand offering doctor-guided GLP-1 weight loss programs to eligible patients in all 50 states.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuuVim +15
73
88
Dose & formulationNuuVim +12
84
96
Clinical oversighteMI Aesthetics +28
70
42
Labs & monitoringeMI Aesthetics +1
51
50
FulfillmenteMI Aesthetics +16
77
61
Contract termseMI Aesthetics +8
55
47
eMI Aesthetics · left barNuuVim · right bar

The numbers

MetriceMI AestheticsNuuVim
WeighScore70.3/10068.2/100
GradeCC
Scorecard rank#104#153
Semaglutide$179/mo (all doses, compounded)$79/mo (all doses, 3-mo plan, new patients only, compounded)
TirzepatideNot disclosed$133/mo (all doses, 3-mo plan, new patients only, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
eMI Aesthetics

Graded #104 · C

Strengths

  • Available to eligible patients in all 50 states
  • Offers both semaglutide and tirzepatide, plus an oral semaglutide option
  • Intake and provider visits run through OpenLoop Health, an established telehealth network

Where it loses points

  • Full per-drug pricing is not shown before intake; only an 'as low as 179/month' starting rate is published
  • No fill pharmacy or named medical director is publicly listed
  • Support appears limited to email, with no phone number or hours published
NuuVim

Graded #153 · C

Strengths

  • Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
  • Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
  • LegitScript Certified and HIPAA-compliant
  • Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
  • Operating legal entity disclosed: NuuVim LLC, Texas governing law

Where it loses points

  • There is no month-to-month plan: every rate is billed as one three-month payment
  • The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
  • The site's own llms.txt advertises pricing, FAQ and terms files that all 404
  • No state count is published
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard